Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last €107.70 EUR
Change Today +0.45 / 0.42%
Volume 19.7K
BIM On Other Exchanges
Symbol
Exchange
BIM is not on other exchanges.
As of 11:35 AM 08/4/15 All times are local (Market data is delayed by at least 15 minutes).

biomerieux (BIM) Snapshot

Open
€107.60
Previous Close
€107.25
Day High
€107.90
Day Low
€106.80
52 Week High
07/20/15 - €109.65
52 Week Low
09/3/14 - €76.32
Market Cap
4.2B
Average Volume 10 Days
24.3K
EPS TTM
€3.42
Shares Outstanding
39.5M
EX-Date
06/5/15
P/E TM
31.5x
Dividend
€1.00
Dividend Yield
0.93%
Current Stock Chart for BIOMERIEUX (BIM)

Related News

No related news articles were found.

biomerieux (BIM) Related Businessweek News

No Related Businessweek News Found

biomerieux (BIM) Details

bioMérieux S.A. provides in vitro diagnostics solutions that determine the source of disease and contamination to enhance patient health and consumer safety worldwide. The company offers reagents, instruments, and software for diagnosing infectious diseases, healthcare-associated infections, antimicrobial resistance, sepsis, acquired immunodeficiency syndrome, hepatitis, acute care and cardiovascular emergencies, and cancer; and for detecting microorganisms in agri-food, pharmaceutical, biotechnology, and cosmetic products. Its technologies and systems include clinical microbiology products, such as automated VITEK 2 system and Etest for the identification of bacteria and analysis of their susceptibility to antibiotics; VITEK MS, a mass spectrometry-based system for the identification of bacteria, fungi, and mycobacteria; culture media products; BacT/ALERT for the culture and detection of bacteria present in blood; Full Microbiology Lab Automation system; and molecular diagnostics products. The company also provides immunoassays products comprising VIDAS, an immunoassay system; and bioNexia and VIKIA range of products for conducting rapid tests. In addition, it offers molecular biology products, including NucliSENS easyMAG and NucliSENS miniMAG for extraction; and ARGENE and NucliSENS EasyQ for amplification and detection. Further, the company offers industrial microbiology products, such as bacteriophages and cytometry products; and TEMPO, an automated microbiological testing system for food-processing applications. Additionally, the company provides Myla, an information technology solution for microbiology laboratories; PREVI Isola, an automated inoculation system for culture media; and PREVI color gram for the automated gram staining of sample slides containing microorganisms. The company, formerly known as B-D Mérieux, was founded in 1963 and is headquartered in Marcy l’Etoile, France. bioMérieux SA is a subsidiary of Institut Mérieux.

8,062 Employees
Last Reported Date: 04/28/15
Founded in 1963

biomerieux (BIM) Top Compensated Officers

Chief Executive Officer, Director and Member ...
Total Annual Compensation: €669.5K
Compensation as of Fiscal Year 2014.

biomerieux (BIM) Key Developments

bioMérieux Receives FDA 510(K) Clearance for VIDAS® 3

bioMérieux announced that VIDAS® 3, the new generation of VIDAS®, received FDA 510(k) clearance. This instrument, which further enriches the offering of the VIDAS® immunoassay product range, VIDAS® and mini VIDAS®, is now commercially available in the United States. VIDAS® 3 features enhanced automation, in particular the pre-analytical section from the barcoded primary tube including dilution, improved traceability and new software capabilities, as well as a quality control program in compliance with laboratory certification standards. Designed with the help of 1,500 immunoassay laboratories, this new-generation instrument has received an enthusiastic reception by laboratory professionals. VIDAS® 3 uses the same reagents as the other instruments in the VIDAS® range. At launch in the U.S., VIDAS® 3 menu features specialty and high medical value tests, such as IDAS® B·R·A·H·M·S PCT™ for the management of septic patients. The single test concept and new features make the VIDAS® 3 particularly well adapted to meet the needs of labs supporting Emergency Departments and Critical Care.

bioMérieux Reports Earnings Results for the Six Months Ended June 30, 2015; Provides Earnings Guidance for the Full Year 2015

bioMérieux reported earnings results for the six months ended June 30, 2015. For the period, consolidated sales amounted to €933 million, up from €781 million in the year-earlier period. This represented growth of 8.1% like-for-like and of 9.1% after changes in the scope of consolidation related to the BioFire and CEERAM acquisitions. Net debt amounted to €274 million at June 30, 2015 after payment of the dividend versus €249 million at December 31, 2014. Based on the current sales outlook, the company is confident that it will meet its objective of reporting between 4.5% and 6.5% organic growth in sales in 2015, at constant exchange rates and scope of consolidation.

bioMérieux Reports Consolidated Earnings Results for the First Quarter Ended March 31, 2015

bioMérieux reported consolidated earnings results for the first quarter ended March 31, 2015. For the quarter, the company reported consolidated sales amounted to €448 million in the first quarter of 2015, up from €371 million in the year-earlier period. Organic growth came to 8.7%, marking a clear acceleration compared with first-quarter 2014. On a reported basis, sales ended the period up 20.8% year-on-year, lifted by the €37 million positive currency effect and the two additional weeks of sales from BioFire, which was acquired and consolidated as of January 16, 2014. At March 31, 2015, after payment of taxes and variable compensation, net debt stood at €283 million.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
BIM:FP €107.70 EUR +0.45

BIM Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Alere Inc $52.68 USD +2.59
Bio-Rad Laboratories Inc $148.97 USD -0.67
Bruker Corp $21.16 USD -0.30
QIAGEN NV €25.89 EUR -0.015
Siemens Ltd 1,489 INR +12.95
View Industry Companies
 

Industry Analysis

BIM

Industry Average

Valuation BIM Industry Range
Price/Earnings 28.4x
Price/Sales 2.2x
Price/Book 2.8x
Price/Cash Flow 28.4x
TEV/Sales 2.0x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact BIOMERIEUX, please visit www.biomerieux.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.